The Model of Performance Predictors of Independent Commercialization Strategy in the Iranian Bio-Pharmaceutical Industry

Medical or therapeutic biology is dedicated to the development of research tools, diagnosis, development and delivery of drugs and vaccines through the use of cellular systems or processes and biological molecules. A very important strategic choice of companies in the biological drug industry is technology trading strategy. Independent commercialization strategy is recognized as one of the trade drugs in the world. The purpose of the present study is to identify predictions for the performance of independent commercialization strategy in Iran's biological industry using a comprehensive method. In this method, after the filtering of the articles, finally 42 studies that directly addressed the performance of independent commercialization in biological drugs entered the analysis phase of the Maxicioda software. After the combination of 68 distinct passwords, and at higher abstraction levels of the passwords in the form of 9 themes (strategic orientation, technology commercialization intelligence, R&D capability, product development knowledge integration, commercialization (production and marketing), The state -supporting mechanism of government and ownership regimes, formal integration and environmental dynamics were set. In order to construct the conceptual model of the research, they were extracted based on the component output, predictive structures of independent trading strategy, how the structures communication, and their measurement indicators were extracted. The validity of the proposed model based on the country's biotechnology experts with the Lavos content validity method and the minimum square minimum technique is: Independent commercial strategy performance predictions with a 91% determination coefficient include: Official integrity and integrity. Innovation, strategic orientation, technology commercialization, R&D capability, production capability and marketing.